1.Maurice-Tison, S, Verdoux, H, Gay, B, Perez, P, Salamon, R, Bourgeois, ML. How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. Br J Gen Pract. 1998;48:1245–1246.
2.Tylee, A, Gastpar, M, Lepine, JP, Mendlewicz, . DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol. 1999;14:139–151.
3.Nierenberg, AA, Keefe, BR, Leslie, VC, et al.Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60:221–225.
4.Fava, GA, Fabbri, S, Sonino, N. Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1019–1027.
5.Fava, M. Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. J Clin Psychiatry. 2003;64(suppl 14):30–34.
6.Judd, LL, Akiskal, HS, Maser, JD, et al.Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as a predictor of rapid relapse. J Affect Disord 1998;50:97–108.
7.Beasley, CM Jr, Koke, SC, Nilsson, ME, Gonzales, JS. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther. 2000;22:1319–1330.
8.Zajecka, JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry. 2000;61 (suppl 2):20–25.
9.Thase, ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr. 2004;9:808–821.
10.Sharpley, AL, Cowen, PJ. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry. 1995;37:85–98.
11.Bauer, M, Forsthoff, A, Baethge, C, et al.Lithium augmentation therapy in refractory depression–update 2002. Eur Arch Psychiatry Clin Neurosci. 2003;253:132–139.
12.Collaborative Working Group on Clinical Trial Evaluations. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry. 1998;59(suppl 12):41–45.
13.Joffe, RT, Schuller, DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 1993;54:269–271.
14.Dimitriou, EC, Dimitriou, CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol. 1998;18:465–469.
15.Marangell, LB. Augmentation of standard depression therapy. Clin Ther. 2000;22(suppl A):A25–A38.
16.Baumgartner, A. Thyroxine and the treatment of affective disorders: an overview of the results of basic and clinical research. Int J Neuropsychoparmacol. 2000;3:149–165.
17.Bauer, M, Whybrow, PC. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry. 2001;2:59–69.
18.Prange, AJ Jr.Novel uses of thyroid hormones in patients with affective disorders. Thyroid. 1996;6:537–543.
19.Markovitz, PJ, Wagner, S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol. 2003;23:207–209.
20.Menza, MA, Kaufman, KR, Castellanos, A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000;61:378–381.
21.Schwartz, TL, Azhar, N, Cole, JK, et al.An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. J Clin Psychiatry. 2004;65:1223–1227.
22.DeBattista, C, Lembke, A, Solvason, HB, Ghebremichael, R, Poirier, J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. 2004;24:87–90.
23.DeBattista, C, Doghramji, K, Menza, MA, et al.Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64:1057–1064.
24.Fava, M, Thase, ME, DeBattista, C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66:85–93.
25.Hamilton, M. Hamilton Depression Scale. In: Guy, W, ed. ECDEU Assessment Manual for Psychopharmacology Revised Edition. Rockville, Md: National Institute of Mental Health, U.S. Department of Health, Education, and Welfare: 1976:179–192.
26.Johns, MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14:540–545.
27.Krupp, LB, LaRocca, NG, Muir-Nash, J, Steinberg, AD. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–11234.
28.Guy, W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, Md. U.S. Department of Health, Education and Welfare; 1976.
29.Mendoza, TR, Wang, XS, Cleeland, CS, et al.The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186–1196.
30.Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.
31.Iosifescu, DV, Nierenberg, AA, Mischoulon, D, et al.An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry. 2005;66:1038–1042.
32.Papakostas, GI, Petersen, TJ, Nierenberg, AA, et al.Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65:217–221.
33.Boutrel, B, Koob, GF. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep. 2004;27:1181–1194.
34.Engber, TM, Dennis, SA, Jones, BE, Miller, MS, Contreras, PC. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine. Neuroscience. 1998;87:905–911.
35.Saletu, B, Frey, R, Krupka, M, et al.Differential effects of a new central adrenergic agonist—modafinil—and D-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharmacol Res. 1989;9:183–195.
36.Deroche-Gamonet, V, Darnaudery, M, Bruino-Slot, L, Piat, F, Le Moal, M, Piazza, PV. Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology (Berl). 2002;161:387–395.
37.Myrick, H, Malcolm, R, Taylor, B, LaRowe, S. Modafinil: preclinical, clinical, and post-marketing surveillance—a review of abuse liability issues. Ann Clin Psychiatry. 2004;16:101–109.